Xuping Xie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7620789/publications.pdf

Version: 2024-02-01

107 papers	14,181 citations	34076 52 h-index	30058 103 g-index
154 all docs	154 docs citations	154 times ranked	18641 citing authors

#	Article	IF	Citations
1	The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature, 2022, 602, 294-299.	13.7	364
2	A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models. Molecular Therapy, 2022, 30, 1897-1912.	3.7	33
3	Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. Nature Communications, 2022, 13, 852.	5.8	92
4	Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. Cell Host and Microbe, 2022, 30, 485-488.e3.	5.1	80
5	Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652.	13.7	117
6	The RNA helicase DHX16 recognizes specific viral RNA to trigger RIG-I-dependent innate antiviral immunity. Cell Reports, 2022, 38, 110434.	2.9	16
7	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. Npj Vaccines, 2022, 7, 41.	2.9	4
8	The arrival of SARS-CoV-2â€“neutralizing antibodies in a currently available commercial immunoglobulin. Journal of Allergy and Clinical Immunology, 2022, 149, 1958-1959.	1.5	10
9	Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Cell Reports, 2022, 39, 110829.	2.9	214
10	Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants. Antimicrobial Agents and Chemotherapy, 2022, 66, e0022222.	1.4	39
11	Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection. Antiviral Research, 2022, 203, 105329.	1.9	2
12	Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2. Nature Communications, 2022, 13, .	5.8	22
13	A Single-Round Infection Fluorescent SARS-CoV-2 Neutralization Test for COVID-19 Serological Testing at a Biosafety Level-2 Laboratory. Viruses, 2022, 14, 1211.	1.5	8
14	Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis. PLoS Pathogens, 2022, 18, e1010627.	2.1	85
15	A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine. Translational Research, 2022, 249, 13-27.	2.2	5
16	Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. Nature Communications, 2022, 13, .	5.8	63
17	Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. Emerging Microbes and Infections, 2022, 11, 1828-1832.	3.0	32
18	Allosteric inhibitors of the main protease of SARS-CoV-2. Antiviral Research, 2022, 205, 105381.	1.9	23

#	Article	IF	Citations
19	Evaluation of a SARS-CoV-2 lateral flow assay using the plaque reduction neutralization test. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115248.	0.8	13
20	Spike mutation D614G alters SARS-CoV-2 fitness. Nature, 2021, 592, 116-121.	13.7	1,380
21	Engineering SARS-CoV-2 using a reverse genetic system. Nature Protocols, 2021, 16, 1761-1784.	5.5	137
22	Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature, 2021, 591, 293-299.	13.7	579
23	Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nature Communications, 2021, 12, 469.	5.8	148
24	A PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation. Scientific Reports, 2021, 11, 2229.	1.6	27
25	Making sense of spike D614G in SARS-CoV-2 transmission. Science China Life Sciences, 2021, 64, 1062-1067.	2.3	8
26	Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nature Medicine, 2021, 27, 620-621.	15.2	562
27	Inhibition of innate immune response ameliorates Zika virus-induced neurogenesis deficit in human neural stem cells. PLoS Neglected Tropical Diseases, 2021, 15, e0009183.	1.3	6
28	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nature Medicine, 2021, 27, 717-726.	15.2	838
29	The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. Npj Vaccines, 2021, 6, 44.	2.9	36
30	SARS-CoV-2 Infects Human EngineeredÂHeart Tissues and Models COVID-19 Myocarditis. JACC Basic To Translational Science, 2021, 6, 331-345.	1.9	121
31	Neutralizing Activity of BNT162b2-Elicited Serum. New England Journal of Medicine, 2021, 384, 1466-1468.	13.9	528
32	A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. Cell, 2021, 184, 2229-2238.e13.	13.5	51
33	Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. JAMA - Journal of the American Medical Association, 2021, 325, 1896.	3.8	125
34	SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature, 2021, 596, 109-113.	13.7	586
35	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature, 2021, 596, 103-108.	13.7	222
36	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature, 2021, 596, 273-275.	13.7	318

#	Article	IF	Citations
37	Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature, 2021, 595, 718-723.	13.7	128
38	BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. New England Journal of Medicine, 2021, 385, 472-474.	13.9	93
39	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. Cell Host and Microbe, 2021, 29, 1151-1161.e5.	5.1	36
40	Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells. Antimicrobial Agents and Chemotherapy, 2021, 65, e0060221.	1.4	37
41	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nature Microbiology, 2021, 6, 1233-1244.	5.9	237
42	SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. New England Journal of Medicine, 2021, 385, 1627-1629.	13.9	346
43	Infection Kinetics and Transmissibility of a Reanimated Dengue Virus Serotype 4 Identified Originally in Wild Aedes aegypti From Florida. Frontiers in Microbiology, 2021, 12, 734903.	1.5	3
44	Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge. PLoS Biology, 2021, 19, e3001284.	2.6	54
45	Evasion of Type I Interferon by SARS-CoV-2. Cell Reports, 2020, 33, 108234.	2.9	742
46	Identifying optimal capsid duplication length for the stability of reporter flaviviruses. Emerging Microbes and Infections, 2020, 9, 2256-2265.	3.0	17
47	A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nature Communications, 2020, 11, 5214.	5.8	179
48	Topoisomerase III-Î² is required for efficient replication of positive-sense RNA viruses. Antiviral Research, 2020, 182, 104874.	1.9	17
49	A cocrystal structure of dengue capsid protein in complex of inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17992-18001.	3.3	18
50	Using recombination-dependent lethal mutations to stabilize reporter flaviviruses for rapid serodiagnosis and drug discovery. EBioMedicine, 2020, 57, 102838.	2.7	22
51	A Zika virus envelope mutation preceding the 2015 epidemic enhances virulence and fitness for transmission. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 20190-20197.	3.3	53
52	A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nature Communications, 2020, 11, 4059.	5.8	266
53	Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. MBio, 2020, 11, .	1.8	63
54	Role of microglia in the dissemination of Zika virus from mother to fetal brain. PLoS Neglected Tropical Diseases, 2020, 14, e0008413.	1.3	27

#	Article	IF	Citations
55	Envelope protein ubiquitination drives entry and pathogenesis of Zika virus. Nature, 2020, 585, 414-419.	13.7	82
56	Design, synthesis and biological evaluation of spiropyrazolopyridone derivatives as potent dengue virus inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127162.	1.0	8
57	An Infectious cDNA Clone of SARS-CoV-2. Cell Host and Microbe, 2020, 27, 841-848.e3.	5.1	617
58	Role of microglia in the dissemination of Zika virus from mother to fetal brain. , 2020, 14, e0008413.		0
59	Role of microglia in the dissemination of Zika virus from mother to fetal brain. , 2020, 14, e0008413.		0
60	Role of microglia in the dissemination of Zika virus from mother to fetal brain. , 2020, 14, e0008413.		0
61	Role of microglia in the dissemination of Zika virus from mother to fetal brain. , 2020, 14, e0008413.		0
62	Role of microglia in the dissemination of Zika virus from mother to fetal brain. , 2020, 14, e0008413.		0
63	Role of microglia in the dissemination of Zika virus from mother to fetal brain. , 2020, 14, e0008413.		0
64	Design, Synthesis, and Biological Evaluation of Substituted 4,6-Dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3â€²-indoline]-2â€²,5(3H)-dione Analogues as Potent NS4B Inhibitors for the Treatment of Dengue Virus Infection. Journal of Medicinal Chemistry, 2019, 62, 7941-7960.	2.9	26
65	Axl Promotes Zika Virus Entry and Modulates the Antiviral State of Human Sertoli Cells. MBio, 2019, 10, .	1.8	88
66	Dengue NS2A Protein Orchestrates Virus Assembly. Cell Host and Microbe, 2019, 26, 606-622.e8.	5.1	68
67	Repurposing an HIV Drug for Zika Virus Therapy. Molecular Therapy, 2019, 27, 2064-2066.	3.7	4
68	Anti-Zika virus RNAi in neural progenitor cells. Cell Research, 2019, 29, 261-262.	5.7	5
69	Genetic and biochemical characterizations of Zika virus NS2A protein. Emerging Microbes and Infections, 2019, 8, 585-602.	3.0	32
70	Zika Virus NS2A-Mediated Virion Assembly. MBio, 2019, 10, .	1.8	51
71	Maternal vaccination and protective immunity against Zika virus vertical transmission. Nature Communications, 2019, 10, 5677.	5.8	32
72	An evolutionary NS1 mutation enhances Zika virus evasion of host interferon induction. Nature Communications, 2018, 9, 414.	5.8	231

#	Article	IF	Citations
73	Potential Mechanisms for Enhanced Zika Epidemic and Disease. ACS Infectious Diseases, 2018, 4, 656-659.	1.8	9
74	Fragile X mental retardation protein is a Zika virus restriction factor that is antagonized by subgenomic flaviviral RNA. ELife, 2018, 7, .	2.8	37
75	A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission. Cell Host and Microbe, 2018, 24, 487-499.e5.	5.1	46
76	Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate. MBio, 2018, 9, .	1.8	74
77	A single-dose plasmid-launched live-attenuated Zika vaccine induces protective immunity. EBioMedicine, 2018, 36, 92-102.	2.7	37
78	Zika Virus Vaccine: Progress and Challenges. Cell Host and Microbe, 2018, 24, 12-17.	5.1	81
79	Using a Virion Assembly-Defective Dengue Virus as a Vaccine Approach. Journal of Virology, 2018, 92, .	1.5	13
80	A Multiplex Microsphere Immunoassay for Zika Virus Diagnosis. EBioMedicine, 2017, 16, 136-140.	2.7	83
81	A cDNA Clone-Launched Platform for High-Yield Production of Inactivated Zika Vaccine. EBioMedicine, 2017, 17, 145-156.	2.7	39
82	A Rapid Zika Diagnostic Assay to Measure Neutralizing Antibodies in Patients. EBioMedicine, 2017, 17, 157-162.	2.7	58
83	Understanding Zika Virus Stability and Developing a Chimeric Vaccine through Functional Analysis. MBio, 2017, 8, .	1.8	76
84	A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nature Medicine, 2017, 23, 763-767.	15.2	242
85	Reverse Genetics of Zika Virus. Methods in Molecular Biology, 2017, 1602, 47-58.	0.4	10
86	RPLP1 and RPLP2 Are Essential Flavivirus Host Factors That Promote Early Viral Protein Accumulation. Journal of Virology, 2017, 91, .	1.5	60
87	Functional Analysis of Glycosylation of Zika Virus Envelope Protein. Cell Reports, 2017, 21, 1180-1190.	2.9	118
88	A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. Nature Communications, 2017, 8, 676.	5.8	125
89	Small Molecules and Antibodies for Zika Therapy. Journal of Infectious Diseases, 2017, 216, S945-S950.	1.9	23
90	An Infectious cDNA Clone of Zika Virus to Study Viral Virulence, Mosquito Transmission, and Antiviral Inhibitors. Cell Host and Microbe, 2016, 19, 891-900.	5.1	252

#	Article	IF	Citations
91	Restriction of Zika Virus by Host Innate Immunity. Cell Host and Microbe, 2016, 19, 566-567.	5.1	27
92	Zika Virus Replicons for Drug Discovery. EBioMedicine, 2016, 12, 156-160.	2.7	77
93	Zika virus produces noncoding RNAs using a multi-pseudoknot structure that confounds a cellular exonuclease. Science, 2016, 354, 1148-1152.	6.0	212
94	Zika Virus: Diagnosis, Therapeutics, and Vaccine. ACS Infectious Diseases, 2016, 2, 170-172.	1.8	76
95	Characterization of Dengue Virus NS4A and NS4B Protein Interaction. Journal of Virology, 2015, 89, 3455-3470.	1.5	116
96	Mapping the Interactions between the NS4B and NS3 Proteins of Dengue Virus. Journal of Virology, 2015, 89, 3471-3483.	1.5	83
97	Targeting dengue virus NS4B protein for drug discovery. Antiviral Research, 2015, 118, 39-45.	1.9	69
98	Determinants of Dengue Virus NS4A Protein Oligomerization. Journal of Virology, 2015, 89, 6171-6183.	1.5	48
99	Two Distinct Sets of NS2A Molecules Are Responsible for Dengue Virus RNA Synthesis and Virion Assembly. Journal of Virology, 2015, 89, 1298-1313.	1.5	90
100	Generation and characterization of mouse monoclonal antibodies against NS4B protein of dengue virus. Virology, 2014, 450-451, 250-257.	1.1	12
101	Dimerization of Flavivirus NS4B Protein. Journal of Virology, 2014, 88, 3379-3391.	1.5	77
102	Membrane Topology and Function of Dengue Virus NS2A Protein. Journal of Virology, 2013, 87, 4609-4622.	1.5	162
103	Rational Design of a Flavivirus Vaccine by Abolishing Viral RNA 2â€²- O Methylation. Journal of Virology, 2013, 87, 5812-5819.	1.5	81
104	Inhibition of Dengue Virus by Targeting Viral NS4B Protein. Journal of Virology, 2011, 85, 11183-11195.	1.5	130
105	A Single Amino Acid in Nonstructural Protein NS4B Confers Virulence to Dengue Virus in AG129 Mice through Enhancement of Viral RNA Synthesis. Journal of Virology, 2011, 85, 7775-7787.	1.5	73
106	Dengue and Zika RNA-RNA Interactomes Reveal Virus Permissive and Restrictive Factors in Human Cells. SSRN Electronic Journal, 0, , .	0.4	0
107	A Trans-Complementation System for SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	1